Medical Marijuana - The Debate Rages On

 

Marijuana is also known as pot, grass and weed. It is officially called cannabis. It is made from the Cannabis sativa plants flowers and leaves. It is illegal in many countries and possession is a crime. Schedule I substances are substances with a high risk of abuse, but no medical use. Numerous studies have demonstrated that marijuana can be used to treat terminal illnesses such as cancer and AIDS. There has been much debate over medical marijuana's pros or cons. To settle the issue, the 1999 IOM report of The Institute of Medicine, Marijuana and Medicine, Assessing Science Base was published by the Institute of Medicine. The report was Cannabis Oil UK Price comprehensive, but it didn't provide an answer. The opposing parties often use a portion of the report to support their arguments in favor of medical marijuana. The report does not address the issue, despite clarifying many points.

Let's look at why medical marijuana shouldn't be illegal.

(1) Marijuana is a naturally occurring herb that has been used for medicinal purposes from South America to Asia over many millennia. In this age of organic and all-natural health buzzwords, a naturally occurring herb like marijuana might be more secure than synthetic drugs.

(2) Marijuana can be used as a powerful treatment agent. Multiple studies have demonstrated that cannabis can be used for pain relief and analgesic purposes. To treat pain. THC, a component in marijuana, has been shown to be effective in treating chronic pain experienced by cancer patients. However, there have been no conclusive studies on acute pain such as trauma or surgery. Some studies have shown that some marijuana components can be used to treat nausea and vomiting. These side effects are common in radiation therapy and chemotherapy for cancer. Research suggests that cannabis could have therapeutic potential in treating neurological diseases such as multiple sclerosis. Some compounds in marijuana have strong therapeutic properties. Cannobidiol is a key component in marijuana. It has antipsychotic and antioxidant properties as well as anticancer properties. Other cannabinoids have been shown to lower intraocular pressure (IOP), a key risk factor for glaucoma. Drugs that contain active ingredients from marijuana have been approved by the US FDA. However, they were created in the laboratory. Marinol, an antiemetic drug, can be used to treat nausea or vomiting due to cancer chemotherapy. Dronabinol is the active ingredient. It's a synthetic delta-9- tetrahydrocannabinol.

(3) The Marijuana Policy Project, an American-based group, is one of the major proponents of medical marijuana. Numerous medical societies and organizations have supported legalization. In their 2008 position paper, the American College of Physicians suggested that Schedule I be reevaluated. ACP supports research into marijuana’s therapeutic potential. It exempts doctors of federal criminal prosecution, civil liability, and professional sanctioning if they prescribe medical marijuana in accordance with state law. Patients who use medical cannabis in compliance with state laws are protected from criminal or civil penalties.

(4) Legal medical marijuana can be used in many countries. This argument is based upon the argument that medical marijuana can be legally used in many countries. Another point that is strong is the legalization of medical marijuana in Canada, Belgium, and the Netherlands. For certain countries, such as Canada, Spain, Israel or Spain, strict prescription restrictions are in effect. Some states allow exemptions.

These are just a few reasons medical marijuana is not a good idea.

(1) Insufficient information regarding safety and effectiveness. Safety is the number one priority in drug regulation. First, safety of marijuana and its constituents needs to be established. The second is efficacy. Second, efficacy. Although marijuana can have positive effects on the health of some people, medically acceptable. If marijuana isn't comparable to other drugs, it may not be possible for the FDA to approve medical marijuana. Robert J. Meyer from the Department of Health and Human Services testified that anyone can access any drug or treatment, regardless of their knowledge or ability. Access to information on safety, efficacy, and proper use does not help patients.

(2) Unknown chemical components Only herbal forms are a way to obtain medical marijuana. Marijuana is included in the category of botanical products just as other herbs. Unpurified botanical products have many problems, such as lot-to lot consistency, lot-to lot consistency, dosage determination potency shelf life, toxicity and lot-to lot consistency. According to the IOM report, marijuana's future as medicine is in its individual components. These include cannabinoids and their synthetic derivatives. It would take so much time and money to identify all the components of marijuana, it would be prohibitively costly to make the drugs that would result. The pharmaceutical industry is not interested in spending money to discover more therapeutic compounds.

(3) The possibility of abuse. The addictive nature of cannabis and marijuana. While it is not as addictive as hard drugs such cocaine, there is still the possibility that cannabis can be used to abuse other substances. This is what IOM's report summarizes.

(4) There are no safe delivery methods. The most common method of delivering marijuana is to smoke. Due to the current anti-smoking laws, this delivery method won't be approved by health authorities. Still under development, safe and reliable delivery systems, such as vaporizers, nebulizers, or inhalers are still being tested.

(5) It's a treatment that only treats symptoms and not cures. While marijuana has therapeutic properties, it is only used to treat symptoms. These conditions are not treated with marijuana. These symptoms can be treated with marijuana. There are other medications that work as well or better than marijuana.

The 1999 IOM report could not resolve the medical marijuana controversy based on the scientific evidence available at the time. Although it strongly discouraged smoking, the report allowed medical marijuana to be used through a medical inhaler or vaporizer. The report suggested that medical supervision be given to patients who are able to use marijuana compassionately. The report also suggested that more money be allocated for research into the safety and efficacy of cannabinoids.

How can I clarify the IOM report's issues? Another review is not something that health authorities seem to be interested in. This data is biased towards safety concerns about the potential harms of smoking marijuana. Only synthetic cannabinoids research (e.g. THC. It is difficult to do an objective risk-benefit analysis.

Because of strict regulations and limited funding, it is often difficult to conduct clinical trials on marijuana. Because of the complicated legalities, very few pharmaceutical companies invest into cannabinoid research. It is not always clear how medical marijuana should defined. It can be used as a plant product, or synthetic cannabinoid compound (e.g. It can also contain THC or its derivatives. Synthetic cannabinoids (e.g. Marinol (a synthetic cannabinoid, e.g. This issue is further complicated due to conspiracy theories surrounding drug regulators, and the pharmaceutical industry.